Discovery of Novel Targets for Aberrant Methylation in Pancreatic Carcinoma Using High-throughput Microarrays

Case ID:
C04187
Disclosure Date:
2/5/2003
C04187: Discovery of Novel Targets for Aberrant Methylation in Pancreatic Carcinoma Using High-throughput Microarrays
Technical Details:
In order to identify potential targets for aberrant methylation in pancreatic cancer, we analyzed global changes in gene expression profiles of 4 pancreatic cancer cell lines after treatment with the demethylating agent 5-aza-2?-deoxycytidine (5Aza-dC) and/or the histone deacetylase inhibitor trichostatin A (TSA). A substantial number of genes were induced 5-fold or greater by 5Aza-dC alone, TSA alone, and by treatment with both agents. The methylation status of 11 of these genes was examined in a panel of 42 pancreatic cancers, and all 11 of these genes were aberrantly methylated in pancreatic cancer but rarely if any methylated in 10 normal pancreatic ductal epithelia.
Looking for Partners:
Cancer Diagnostics
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Aberrantly Methylated Genes in Pancreatic Cancer PCT: Patent Cooperation Treaty United States 10/548,976 7,485,418 6/23/2006 2/3/2009 3/17/2024 Granted
Aberrantly Methylated Genes in Pancreatic Cancer DIV: Divisional United States 12/351,709 8,785,614 1/9/2009 7/22/2014 3/17/2024 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Anum Afzal
aafzal7@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum